BHC Stock Analysis: Buy, Sell, or Hold?
BHC - Bausch Health Companies Inc
$5.03
0.01 (0.20%)
▲
5d:
-1.37%
30d:
-15.18%
90d:
-30.14%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 29, 2026
29d
Smart Money Accumulation
BHC is down 3.7% this week, but smart money is accumulating calls. Top strike: $6 2026-05-01 with 41 OI. Call ratio: 87% View Scanner →
Strength: 5.6/10
Get Alerted When BHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BHC appears deeply undervalued. Market expects -6.0% annual earnings decline despite 1368% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: BHC appears deeply undervalued. Market expects -6.0% annual earnings decline despite 1368% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.39
Based on -2.1% avg growth
INTRINSIC VALUE TODAY
$3.35
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BHC is currently trading at $5.03, which is considered oversold relative to its 30-day fair value range of $5.02 to $5.85. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.2) compared to its historical average (1.5). Remarkably, the market is currently pricing in an annual earnings decline of 6.0% over the next few years. This pessimistic expectation contrasts with the company's recent 1368.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BHC is in a strong uptrend. The price is currently testing key support at $4.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.71 (+53.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BHC is in a strong uptrend. The price is currently testing key support at $4.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.71 (+53.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.02 -
$5.85
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 53.7% below Wall St target ($7.71)
Fair Price Analysis
30-Day Fair Range
$5.02 -
$5.85
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.93
Resistance Level
$5.29
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.25
Wall Street Target
$7.71
(+53.7%)
Revenue Growth (YoY)
9.3%
Earnings Growth (YoY)
1368.0%
Profit Margin
1.5%
Valuation Discount vs History
-6.0% cheaper
PE vs Historical
1.3 vs 1.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.0%
(market-implied from PE analysis)
1-Year Target
$4.72
(-6%)
2-Year Target
$4.44
(-12%)
3-Year Target
$4.17
(-17%)
3-Yr Target (if PE normalizes)
(PE: 1→2)
$5.01
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: -8.2%)
$69.57
(+1286%)
Base:
(SPY PE: 1.2, Growth: -8.2%)
$3.88
(-23%)
Bear:
(PE: 1.1, Growth: -8.2%)
$3.30
(-34%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (1x PE) as earnings recover.
Trailing PE: 11.93 | Current EPS (TTM): $0.42
Bull Case
$11.02
(+116%)
Analyst growth 100.0%, PE expands to 13.1
Base Case
$10.02
(+97%)
Market implied 100.0%, PE stable at 11.9
Bear Case
$3.41
(-33%)
Severe decline -20.0%, PE contracts to 10.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.2 to 1.5
Stabilization Target:
$6.03
(+20.0%)
PE Expansion Potential:
+20.0%
Share & Embed Analysis
Last updated: March 30, 2026 4:30 PM ET
Data refreshes hourly during market hours. Next update: 5:30 PM
Data refreshes hourly during market hours. Next update: 5:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced BHC Option Strategies
Professional options setups generated by AI based on today's BHC price and gamma walls.
